Stockscreener 앱 받기
5.05
1.17%
-0.06
Clene Inc 주식(CLNN)의 최신 뉴스
Nanotechnology Stocks Worth WatchingJanuary 17th - MarketBeat
Growth Value: Will PG E Corporation Preferred Security benefit from rising consumer demandSell Signal & Intraday High Probability Alerts - baoquankhu1.vn
Trading Action: Is Clene Inc exposed to currency risksEarnings Growth Report & High Conviction Investment Ideas - baoquankhu1.vn
Clene Inc. ten percent owner sells $292,184 in shares By Investing.com - Investing.com Nigeria
Shorts Report: Will CLNN stock recover after earningsMarket Movement Recap & Weekly Return Optimization Plans - baoquankhu1.vn
Aug Technicals: Is Clene Inc Equity Warrant stock a smart retirement pickWeekly Risk Summary & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Best Nanotechnology Stocks Worth WatchingJanuary 16th - MarketBeat
Clene Inc. ten percent owner sells $292,184 in shares - Investing.com
Top Nanotechnology Stocks To Add to Your WatchlistJanuary 4th - MarketBeat
Clene to Present at the Emerging Growth Conference - The Manila Times
Best Nanotechnology Stocks To Follow TodayJanuary 15th - MarketBeat
Clene, FDA to discuss survival data and approval path for CNM-Au8 - ALS News Today
Winners Losers: Is Clene Inc a top pick in the sectorGap Up & Long-Term Growth Stock Strategies - baoquankhu1.vn
Risks Report: Is Clene Inc Equity Warrant stock positioned well for digital economyWeekly Profit Summary & AI Forecasted Entry/Exit Points - Bộ Nội Vụ
Clene (NASDAQ:CLNN) Director David Matlin Purchases 33,333 Shares of Stock - MarketBeat
Insider Buying: David Matlin Acquires Shares of Clene Inc (CLNN) - GuruFocus
Clene Announces Multi-Tranche Financing to Extend Cash Runway - TipRanks
Clene Signs Multiple Financing Agreements - TradingView — Track All Markets
Forecast Cut: Is Clene Inc. stock dividend yield sustainableQuarterly Profit Report & High Accuracy Investment Entry Signals - Bộ Nội Vụ
Promising Nanotechnology Stocks To Follow NowJanuary 13th - MarketBeat
FDA grants Clene in-person meeting to discuss ALS drug biomarker data - Investing.com Nigeria
Published on: 2026-01-13 07:04:12 - Улправда
Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $19,457.55 in Stock - MarketBeat
Clene Inc. ten percent owner sells $256k in shares - Investing.com
Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells 32,705 Shares of Stock - MarketBeat
Clene (NASDAQ:CLNN) Major Shareholder Sells $56,900.25 in Stock - MarketBeat
Clene Inc. ten percent owner sells $256k in shares By Investing.com - Investing.com India
Clene Insider Sold Shares Worth $256,235, According to a Recent SEC Filing - marketscreener.com
Nanotechnology Stocks To ResearchJanuary 12th - MarketBeat
Clene (CLNN) Secures FDA Type C Meeting for ALS Treatment Review - GuruFocus
Clene Advances CNM-Au8 ALS Program with FDA Meeting - TipRanks
Clene announces additional Cnm-Au8 biomarker data supporting potential NDA filing for upcoming in-person FDA meeting - marketscreener.com
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting - The Manila Times
Clene Inc Announces Additional CNM-Au8 Biomarker Data for FDA Meeting - TradingView — Track All Markets
Promising Nanotechnology Stocks To Add to Your WatchlistJanuary 11th - MarketBeat
Top Nanotechnology Stocks To Follow TodayJanuary 8th - MarketBeat
Clene secures $28 million in registered direct offering for ALS drug - Investing.com Nigeria
Is Clene Inc. (84C0) stock a defensive play amid uncertainty2025 Volume Leaders & AI Powered Market Trend Analysis - Улправда
Chart Watch: Will Aterian Inc stock see PE expansionWatch List & Short-Term Trading Alerts - moha.gov.vn
Best Nanotechnology Stocks To Follow NowJanuary 9th - MarketBeat
Clene (CLNN) Secures $28 Million Through Direct Offering - GuruFocus
D. Boral Capital Maintains 'Buy' Rating for CLNN with $23 Target - GuruFocus
Clene announces registered direct offering of over $28 million - marketscreener.com
D. Boral Capital Reiterates Buy Rating for Clene (NASDAQ:CLNN) - MarketBeat
Clene secures $28 million in registered direct offering for ALS drug By Investing.com - Investing.com South Africa
Clene Inc. Announces Oversubscribed Registered Direct Offering Exceeding $28 Million to Fund ALS Treatment Development - Quiver Quantitative
Clene Announces Registered Direct Offering of Over $28 Million - marketscreener.com
Biotech Clene raises $28M ahead of potential FDA decision on ALS drug - Stock Titan
Can Clene Inc. Equity Warrant stock weather global recessionEarnings Recap Report & Growth-Oriented Investment Plans - Улправда
Will Clene Inc. Equity Warrant stock reach Wall Street targetsJobs Report & Free Long-Term Investment Growth Plans - Улправда
Chipmakers Recap: Is Clene Inc. (84C0) stock a top hedge fund pickMarket Weekly Review & Long Hold Capital Preservation Plans - Улправда
How Clene Inc. Equity Warrant stock reacts to Fed rate cutsJuly 2025 Drop Watch & Daily Price Action Insights - Улправда
Why Clene Inc. Equity Warrant stock remains on buy listsEarnings Trend Report & Fast Exit and Entry Strategy Plans - Улправда
Will Clene Inc. stock gain from strong economyStop Loss & AI Based Buy/Sell Signal Reports - Улправда
Is Clene Inc. Equity Warrant stock a buy before product launchesJuly 2025 Highlights & Low Risk Profit Maximizing Plans - Улправда
Why Clene Inc. (84C0) stock stays undervalued2025 Buyback Activity & Reliable Entry Point Trade Alerts - Улправда
How Clene Inc. stock reacts to Fed rate cutsPortfolio Gains Report & Risk Controlled Swing Alerts - ulpravda.ru
Published on: 2026-01-08 21:03:18 - Улправда
Chidozie Ugwumba Sells 3,111 Shares of Clene (NASDAQ:CLNN) Stock - MarketBeat
Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 5,869 Shares - MarketBeat
Clene Inc. ten percent owner Ugwumba sells $78k in shares - Investing.com Canada
4.73%
0.92%
자본화:
|
볼륨(24시간):